The Current Ratio as of November 2024 (TTM) for Pardes Biosciences, Inc. (PRDS) is 9.81

According to Pardes Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.81. This represents a change of -68.54% compared to the average of 31.19 of the last 4 quarters.

Pardes Biosciences, Inc. (PRDS) Historical Current Ratio (quarterly & annually)

How has PRDS Current Ratio performed in the past?

The mean historical Current Ratio of Pardes Biosciences, Inc. over the last ten years is 13.58. The current 9.81 Current Ratio has changed 7.13% with respect to the historical average. Over the past ten years (40 quarters), PRDS's Current Ratio was at its highest in in the June 2023 quarter at 81.72. The Current Ratio was at its lowest in in the March 2021 quarter at 0.13.

Pardes Biosciences, Inc. (PRDS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Pardes Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pardes Biosciences, Inc. (PRDS) Average Current Ratio

How has PRDS Current Ratio performed in the past?

The current Current Ratio of Pardes Biosciences, Inc. (PRDS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Pardes Biosciences, Inc. (PRDS) Current Ratio vs. Peers

How is PRDS’s Current Ratio compared to its peers?

Pardes Biosciences, Inc.’s Current Ratio is greater than Shattuck Labs, Inc. (7.96), less than Eliem Therapeutics, Inc. (60.41), greater than Champions Oncology, Inc. (0.69), less than Century Therapeutics, Inc. (10.39), less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (12.90), greater than Achilles Therapeutics plc (6.04), greater than NextCure, Inc. (9.07), greater than Assembly Biosciences, Inc. (2.36), greater than CytomX Therapeutics, Inc. (1.04), greater than Nuvation Bio Inc. (9.57), greater than Ovid Therapeutics Inc. (5.66), less than Connect Biopharma Holdings Limited (12.04),

Build a custom stock screener for Pardes Biosciences, Inc. (PRDS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pardes Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pardes Biosciences, Inc. (PRDS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pardes Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.